Aspen Neuroscience's David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting

Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13^th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons.

“There was a great turnout at David’s poster at SFN 2022, a session packed with invigorating and collaborative discussions, independent scientific validation and appreciation of our iPSC platform. Many walked away with a better understanding of Aspen’s commitment to developing iPSC-derived cell therapy to address diseases with high unmet medical need, beginning with autologous neuron replacement treatment for both idiopathic and genetic forms of Parkinson’s disease,” said Aspen Neuroscience’s Chief Scientific Officer, Xiaokui Zhang, PhD.

SFN’s annual conference is held each year for scientists from around the world to congregate to discover new ideas, share their research, and experience the best the field has to offer.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.